The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | |||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | ||||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | FIGI | (to the nearest dollar) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
AMBRX BIOPHARMA INC | SPONSORED ADS | 02290A102 | 100,836,791 | 11,304,573 | SH | SOLE | 11,304,573 | 0 | 0 | |||
ARGENX SE | SPONSORED ADR | 04016X101 | 106,259,071 | 285,198 | SH | SOLE | 285,198 | 0 | 0 | |||
KEROS THERAPEUTICS INC | COM | 492327101 | 1,340,182 | 31,386 | SH | SOLE | 31,386 | 0 | 0 | |||
TG THERAPEUTICS INC | COM | 88322Q108 | 157,186,665 | 10,451,241 | SH | SOLE | 10,451,241 | 0 | 0 |